These Were the 3 Top-Performing Stocks in the Nasdaq Composite in August 2025

The Nasdaq Composite advanced 1.58% in August, primarily driven by strong performances from Intel, Applovin, and IDEXX Laboratories. Intel's gains were fueled by a strategic U.S. government investment for an approximate 10% equity stake and a $2 billion investment from SoftBank, aimed at bolstering domestic semiconductor manufacturing. Applovin reported robust Q2 results with revenue surging 77% year-over-year to $1.26 billion and net income increasing 164% to $820 million, while IDEXX Laboratories raised its full-year guidance following an 11% Q2 revenue increase to $1.1 billion.

Analysis

The Nasdaq Composite's 1.58% gain in August was significantly influenced by standout performances from specific technology and healthcare firms, with Intel (INTC), Applovin (APP), and IDEXX Laboratories (IDXX) each posting gains of at least 21%. Intel's rally was catalyzed by substantial external capital, including a U.S. government investment for an approximate 10% equity stake and a $2 billion investment from SoftBank, both aimed at enhancing its domestic semiconductor manufacturing capabilities to compete with industry leaders like Taiwan Semiconductor. In contrast, Applovin's surge was fundamentally driven by a robust second-quarter report, featuring a 77% year-over-year revenue increase to $1.26 billion, a 164% rise in net income to $820 million, and a near tripling of its EPS to $2.39. IDEXX Laboratories also demonstrated strong operational performance, with Q2 revenue growing 11% year-over-year to $1.1 billion, prompting the company to raise its full-year revenue guidance by approximately $90 million to a range of $4.2 billion to $4.28 billion.

Key Decisions for Investors

• Applovin's exceptional 77% year-over-year revenue growth and tripling of EPS signal strong fundamental momentum, prompting investors to assess the sustainability of this ad-tech growth and whether it is fully priced in at current valuations.
• Intel's recent appreciation is primarily driven by strategic government and private investments rather than recent operational outperformance, so investors should weigh the long-term execution risk and the company's ability to effectively deploy this capital to compete with established players like TSM.
• IDEXX Laboratories' upward revision of its full-year revenue and earnings guidance provides increased confidence in its forward-looking performance, making it a consideration for portfolios seeking stable growth and positive earnings visibility.